NCT02951156 (Javelin DLBCL) is a Phase 3 clinical trial of Avelumab in Diffuse Large B-Cell Lymphoma, sponsored by Pfizer.

Who is sponsoring NCT02951156?

NCT02951156 is sponsored by Pfizer.

What drugs are being tested in NCT02951156?

Interventions in NCT02951156: Avelumab, Utomilumab, Rituximab, Azacitidine, Bendamustine, Gemcitabine, Oxaliplatin.

What condition does NCT02951156 study?

NCT02951156 studies Diffuse Large B-Cell Lymphoma.

Is NCT02951156 still recruiting?

NCT02951156 is currently terminated. Last updated 17 December 2020.

Are results published for NCT02951156?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-12-17 · How we verify

NCT02951156: Javelin DLBCL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

Terminated Phase 3 Results posted Last updated 17 December 2020

What this trial tests

Phase 3 trial testing Avelumab in Diffuse Large B-Cell Lymphoma in 29 participants. Terminated before completion.

Timeline

16 December 2016

Primary endpoint
2 December 2019

2 December 2019

Quick facts

Lead sponsor	Pfizer
Phase	Phase 3
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	29
Start date	16 December 2016
Primary completion	2 December 2019
Estimated completion	2 December 2019
Sites	29 locations across Italy, Belgium, United Kingdom, Poland, South Korea, Australia, United States, Spain

Drugs / interventions tested

Avelumab (avelumab) — full drug profile →
Utomilumab
Rituximab
Azacitidine (azacitidine) — full drug profile →
Bendamustine (BENDAMUSTINE) — full drug profile →
Gemcitabine (gemcitabine) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →

Conditions studied

Diffuse Large B-Cell Lymphoma — all drugs for Diffuse Large B-Cell Lymphoma →

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Diffuse Large B-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Dose Limiting Toxicities (DLT) Primary · Day 1 Cycle 1 up to 4 Weeks

AEs occurring in first 4 weeks of treatment,attributable to 1 of study drugs. Hematology:1)Grade 4 neutropenia,2)Grade \>=3 febrile neutropenia with single temperature of \>38.3 degrees Celsius (C)/sustained temperature of \>=38.0 degrees C for more than 1 hour with/without associated sepsis,3)Grade \>=3 neutropenic infection,4)Grade 4 thrombocytopenia/Grade 3 thrombocytopenia with clinically significant bleeding,5)Grade 4 anemia 6)Any grade \>=3 non-hematology toxicity except:transient Grade 3 flu like symptoms/fever controlled with standard medical management;transient Grade 3 fatigue,locali

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	1
Avelumab+Azacitidine+Utomilumab	0
Avelumab+Bendamustine+Rituximab	0

Objective Response Rate (ORR) as Assessed by Investigator Per Lugano Response Classification Criteria Primary · Randomization until date of PD, start of new anticancer therapy, discontinuation from study or death due to any cause, whichever occurred first (maximum up to 36 months)

ORR was defined as percentage of participants with complete response (CR) or partial response (PR), as assessed by investigator per lugano response classification criteria. CR was defined as a score of 1 (no uptake above background), 2 (uptake less than or equal to \[\<=\] mediastinum), or 3 (uptake less than \[\<\] mediastinum but \<=liver) with or without a residual mass on PET 5-point scale (5-PS), for lymph nodes and extralymphatic sites; no new lesions; no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. PR was defined as \>=50% decrease in SPD of up to six of the largest

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	11.1	0.3 – 48.2
Avelumab+Azacitidine+Utomilumab	0	0.0 – 33.6
Avelumab+Bendamustine+Rituximab	27.3	6.0 – 61.0

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Greater Than or Equal to (>=) Grade 3, As Per National Cancer Institute Common Terminology Criteria For Adverse Events (NCI-CTCAE), Version 4.03 Secondary · From first dose of study treatment up to at least 30 days after the last dose of study treatment or initiation of new anti-cancer therapy (up to 36 months)

AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. As per NCI-CTCAE version 4.03,severity was graded as Grade 1:asymptomatic/mild symptoms,clinical/diagnostic observations only, intervention not indicated; Grade 2:moderate, minimal, local/noninvasive intervention indicated,limiting age-appropriate instrumental activities of daily life (ADL); Grade 3:severe/medically significant but not immediately life-threatening, hospitalization/prolongation of existing hospitalization indicated, disabling, limiting self-care

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	4
Avelumab+Azacitidine+Utomilumab	7
Avelumab+Bendamustine+Rituximab	10

Number of Participants With Laboratory Abnormalities As Per National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.03 Secondary · From first dose of study treatment up to at least 30 days after the last dose of study treatment or initiation of new anti-cancer therapy (up to 36 months)

Laboratory parameters included hematological and biochemistry: Hematological parameters included: anemia, haemoglobin increased, lymphocyte count decreased, lymphocyte count increased, neutrophil count decreased, platelet count decreased and white blood cells decreased. Biochemistry parameters included alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, blood bilirubin increased, cholesterol high, creatine kinase(cpk) increased, creatinine increased, gamma glutamyl transferase(ggt) increased, hypercalcemia, hyperglycemia, hyperkalemia, hype

Anemia

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	6
Avelumab+Azacitidine+Utomilumab	8
Avelumab+Bendamustine+Rituximab	10

Hemoglobin increased

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	0
Avelumab+Azacitidine+Utomilumab	0
Avelumab+Bendamustine+Rituximab	0

Lymphocyte count decreased

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	4
Avelumab+Azacitidine+Utomilumab	7
Avelumab+Bendamustine+Rituximab	9

Lymphocyte count increased

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	0
Avelumab+Azacitidine+Utomilumab	0
Avelumab+Bendamustine+Rituximab	0

Neutrophil count decreased

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	2
Avelumab+Azacitidine+Utomilumab	2
Avelumab+Bendamustine+Rituximab	9

Platelet count decreased

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	4
Avelumab+Azacitidine+Utomilumab	3
Avelumab+Bendamustine+Rituximab	8

White blood cell decreased

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	1
Avelumab+Azacitidine+Utomilumab	4
Avelumab+Bendamustine+Rituximab	8

Alanine aminotransferase increased

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	2
Avelumab+Azacitidine+Utomilumab	5
Avelumab+Bendamustine+Rituximab	2

Number of Participants With Electrocardiogram (ECG) Abnormalities Secondary · From first dose of study treatment up to at least 30 days after the last dose of study treatment or initiation of new anti-cancer therapy (up to 36 months)

ECG abnormalities included: 1) QT interval, QT interval corrected using Bazett's formula (QTcB) and QT interval corrected using Fridericia's formula (QTcF): increase from baseline greater than (\>) 30 millisecond (ms) or 60 ms; absolute value \>450 ms, \>480 ms and \>500 ms; 2) heart rate (HR): absolute value \<=50 beats per minute (bpm) and decrease from baseline \>=20 bpm; absolute value \>=120 bpm and increase from baseline \>=20 bpm; 3) PR interval: absolute value \>=220 ms and increase from baseline \>=20 ms; 4) QRS interval: absolute value \>=120 ms.

QT: Increase from baseline >30 ms

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	4
Avelumab+Azacitidine+Utomilumab	4
Avelumab+Bendamustine+Rituximab	4

QT: Increase from baseline >60 ms

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	1
Avelumab+Azacitidine+Utomilumab	3
Avelumab+Bendamustine+Rituximab	2

QT: >450 ms

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	2
Avelumab+Azacitidine+Utomilumab	2
Avelumab+Bendamustine+Rituximab	2

QT: >480 ms

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	0
Avelumab+Azacitidine+Utomilumab	1
Avelumab+Bendamustine+Rituximab	1

QT: >500 ms

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	0
Avelumab+Azacitidine+Utomilumab	0
Avelumab+Bendamustine+Rituximab	0

QTcB: Increase from baseline >30 ms

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	1
Avelumab+Azacitidine+Utomilumab	3
Avelumab+Bendamustine+Rituximab	4

QTcB: Increase from baseline >60 ms

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	1
Avelumab+Azacitidine+Utomilumab	1
Avelumab+Bendamustine+Rituximab	0

QTcB: >450 ms

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	4
Avelumab+Azacitidine+Utomilumab	5
Avelumab+Bendamustine+Rituximab	9

Duration of Response (DOR) as Assessed by Investigator Per Lugano Response Classification Criteria Secondary · First response (CR or PR) to date of PD, start of new anti-cancer therapy, discontinuation from the study, censoring date or death due to any cause, whichever occurred first (maximum up to 36 months)

Investigator assessed DOR: was defined for participants with OR as time from first documentation of OR to time of first documentation of disease progression/death due to any cause, whichever occurred first. CR: score of 1(no uptake above background),2(uptake \<=mediastinum),or 3(uptake \<mediastinum but \<=liver) with or without a residual mass on PET 5-PS,for lymph nodes extralymphatic sites;no new lesions;no evidence of FDG-avid disease in bone marrow. PR: \>=50% decrease in SPD of up to 6 of largest dominant lymph nodes,no increase in size of other nodes,liver,spleen volume,\>=50% decrease

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	1.81	1.81 – 1.81
Avelumab+Bendamustine+Rituximab	NA	NA – NA

Time to Tumor Response (TTR) as Assessed by Investigator Per Lugano Response Classification Criteria Secondary · From the date of randomization to the first documentation of objective response (CR or PR) (maximum up to 36 months)

TTR was defined for participants who achieved objective response as time from randomization to first documentation of objective tumor response (CR or PR) that was subsequently confirmed. CR was defined as a score of 1 (no uptake above background), 2 (uptake \<= mediastinum), or 3 (uptake \<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow. PR was defined as \>=50% decrease in SPD of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	1.8	1.8 – 1.8
Avelumab+Bendamustine+Rituximab	1.9	1.7 – 2.6

Disease Control Rate as Assessed by the Investigator Per Lugano Response Classification Criteria Secondary · From the date of randomization to the first documentation of PD, study discontinuation, start of new anti-cancer therapy or death due to any cause, whichever occurred first (maximum up to 36 months)

Disease control rate was defined as percentage of participants with disease control. Disease Control (DC) was defined as the best overall response of CR, PR, or stable disease (SD). CR: score of 1 (no uptake above background), 2 (uptake \<= mediastinum), or 3 (uptake less than \<mediastinum but \<=liver) with or without a residual mass on PET 5-PS, for lymph nodes and extralymphatic sites; no new lesions; no evidence of FDG-avid disease in bone marrow. PR: \>=50% decrease in SPD of up to six of the largest dominant lymph nodes, no increase in size of other nodes, liver, or spleen volume, a \>=

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	22.2	2.8 – 60.0
Avelumab+Azacitidine+Utomilumab	0	0 – 33.6
Avelumab+Bendamustine+Rituximab	36.4	10.9 – 69.2

Progression-Free Survival (PFS) as Assessed by the Investigator Per Lugano Response Classification Criteria Secondary · From the date of randomization to progression of disease, study discontinuation, censoring date or death due to any cause, whichever occurred first (up to 36 months)

Investigator assessed PFS was defined as time (in months) from date of randomization to the first documentation of disease progression or death (due to any cause), whichever occurred first. PFS data was censored on the date of the last adequate tumor assessment for participants who had no an event (PD or death), for participants who start a new anti-cancer therapy prior to an event or for participants with an event after 2 or more missing or inadequate post-baseline tumor assessment. Participants without an adequate baseline or post-baseline tumor assessment were censored on the date of random

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	1.8	0.6 – 3.5
Avelumab+Azacitidine+Utomilumab	1.5	0.3 – 1.8
Avelumab+Bendamustine+Rituximab	2.7	1.3 – NA

Overall Survival Secondary · From the date of randomization to discontinuation from the study or death, whichever occurred first (maximum up to 36 months)

Overall survival was defined as the time (in months) from the date of randomization to the date of death due to any cause. Participants last known to be alive were censored at date of last contact. Analysis was performed using Kaplan-Meier method.

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	14.8	0.9 – NA
Avelumab+Azacitidine+Utomilumab	4.0	0.3 – 11.3
Avelumab+Bendamustine+Rituximab	5.2	1.3 – NA

Concentration Verses Time Summary of Avelumab Secondary · 1 hour Post dose Day 2 Cycle 1, 144 hour Post dose Day 8 of Cycle 1, 0 hour Post dose Day 16 of Cycle 1, Day 1 of Cycle 4 and Cycle 6

Cycle 1 Day 2

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	183.29	± 83.809
Avelumab+Azacitidine+Utomilumab	198.43	± 29.387
Avelumab+Bendamustine+Rituximab	193.30	± 29.702

Cycle 1 Day 8

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	75.14	± 21.357
Avelumab+Azacitidine+Utomilumab	68.44	± 18.553
Avelumab+Bendamustine+Rituximab	65.33	± 17.913

Cycle 1 Day 16

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	25.33	± 13.197
Avelumab+Azacitidine+Utomilumab	26.53	± 9.237
Avelumab+Bendamustine+Rituximab	19.36	± 7.810

Cycle 4 Day 1

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	25.00	± 4.667
Avelumab+Azacitidine+Utomilumab	62.00	± NA
Avelumab+Bendamustine+Rituximab	120.88	± 165.187

Cycle 6 Day 1

Group	Value	95% CI
Avelumab+Azacitidine+Utomilumab	7.57	± NA
Avelumab+Bendamustine+Rituximab	39.43	± 18.327

Number of Participants With Anti-Drug Antibodies (ADA) Against Avelumab by Never and Ever Positive Status Secondary · Baseline: 2 hours pre-dose of first dose of avelumab, Post baseline: post first dose up to up to 30 Days after the end of treatment (maximum up to 36 months)

ADA never-positive was defined as no positive ADA results at any time point. ADA ever-positive was defined as at least one positive ADA result at any time point.

Baseline: ADA ever-positive

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	0
Avelumab+Azacitidine+Utomilumab	0
Avelumab+Bendamustine+Rituximab	1

Baseline: ADA never-positive

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	8
Avelumab+Azacitidine+Utomilumab	9
Avelumab+Bendamustine+Rituximab	10

Post Baseline: ADA ever-positive

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	0
Avelumab+Azacitidine+Utomilumab	0
Avelumab+Bendamustine+Rituximab	0

Post Baseline: ADA never-positive

Group	Value	95% CI
Avelumab+Rituximab+Utomilumab	8
Avelumab+Azacitidine+Utomilumab	9
Avelumab+Bendamustine+Rituximab	11

Adverse events — posted to ClinicalTrials.gov

Time frame: Baseline up to follow up (36 months). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Avelumab+Rituximab+Utomilumab

Serious: 3/8 (38%)

Deaths: 4/8

Avelumab+Azacitidine+Utomilumab

Serious: 6/9 (67%)

Deaths: 8/9

Avelumab+Bendamustine+Rituximab

Serious: 7/11 (64%)

Deaths: 6/11

Serious adverse events (25 terms)

Reaction	System	Avelumab+Rituximab+Utomilu…	Avelumab+Azacitidine+Utomi…	Avelumab+Bendamustine+Ritu…
Disease progression	General disorders	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—
Bronchitis	Infections and infestations	—	—	—
Death	General disorders	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—
Fatigue	General disorders	—	—	—
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—
Herpes zoster	Infections and infestations	—	—	—
Hypercalcaemia	Metabolism and nutrition disorders	—	—	—
Laryngeal oedema	Respiratory, thoracic and mediastinal disorders	—	—	—
Non-Hodgkin's lymphoma	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—
Ophthalmic herpes zoster	Infections and infestations	—	—	—
Pain	General disorders	—	—	—
Pneumonia	Infections and infestations	—	—	—
Pyrexia	General disorders	—	—	—
Respiratory failure	Respiratory, thoracic and mediastinal disorders	—	—	—
Sepsis	Infections and infestations	—	—	—
Septic shock	Infections and infestations	—	—	—
Small intestinal obstruction	Gastrointestinal disorders	—	—	—
Superior vena cava syndrome	Vascular disorders	—	—	—
Syncope	Nervous system disorders	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—
Urinary tract infection	Infections and infestations	—	—	—
Gastrointestinal haemorrhage	Gastrointestinal disorders	—	—	—

Other adverse events (132 terms — click to expand)

Reaction	System	Avelumab+Rituximab+Utomilu…	Avelumab+Azacitidine+Utomi…	Avelumab+Bendamustine+Ritu…
Constipation	Gastrointestinal disorders	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—
Fatigue	General disorders	—	—	—
Nausea	Gastrointestinal disorders	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—
Chills	General disorders	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—
Lymphocyte count decreased	Investigations	—	—	—
Pyrexia	General disorders	—	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—	—
Alanine aminotransferase increased	Investigations	—	—	—
Aspartate aminotransferase increased	Investigations	—	—	—
Asthenia	General disorders	—	—	—
Blood alkaline phosphatase increased	Investigations	—	—	—
Blood creatine phosphokinase increased	Investigations	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—
Gamma-glutamyltransferase increased	Investigations	—	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—	—
Hypophosphataemia	Metabolism and nutrition disorders	—	—	—
Hypotension	Vascular disorders	—	—	—
Leukopenia	Blood and lymphatic system disorders	—	—	—
Neutrophil count decreased	Investigations	—	—	—
Platelet count decreased	Investigations	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—
Abdominal discomfort	Gastrointestinal disorders	—	—	—
Abdominal distension	Gastrointestinal disorders	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—
Abdominal pain upper	Gastrointestinal disorders	—	—	—
Acute kidney injury	Renal and urinary disorders	—	—	—
Amylase increased	Investigations	—	—	—
Anxiety	Psychiatric disorders	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—

Most-reported serious reactions: Disease progression, Anaemia, Bronchitis, Death, Decreased appetite, Dyspnoea, Fatigue, Febrile neutropenia.

Data from ClinicalTrials.gov NCT02951156 adverse events section.

Sponsor's own description

Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immune checkpoint inhibitors: recent progress and potential biomarkers.
Darvin P, Toor SM, Sasidharan Nair V, Elkord E. · · 2018 · cited 1495× · PMID 30546008 · DOI 10.1038/s12276-018-0191-1
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Alsaab HO, Sau S, Alzhrani R, Tatiparti K, et al · · 2017 · cited 1206× · PMID 28878676 · DOI 10.3389/fphar.2017.00561
Antibodies to watch in 2020.
Kaplon H, Muralidharan M, Schneider Z, Reichert JM. · · 2020 · cited 332× · PMID 31847708 · DOI 10.1080/19420862.2019.1703531
Antibodies to watch in 2019.
Kaplon H, Reichert JM. · · 2019 · cited 324× · PMID 30516432 · DOI 10.1080/19420862.2018.1556465
Immune checkpoint therapy in liver cancer.
Xu F, Jin T, Zhu Y, Dai C. · · 2018 · cited 299× · PMID 29843754 · DOI 10.1186/s13046-018-0777-4
Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z, Wu X. · · 2020 · cited 147× · PMID 32875727 · DOI 10.1002/cam4.3410
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R, Netti GS, Spadaccino F, Porta C, et al · · 2020 · cited 142× · PMID 33162990 · DOI 10.3389/fimmu.2020.574271
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies.
Wang H, Kaur G, Sankin AI, Chen F, et al · · 2019 · cited 138× · PMID 31186046 · DOI 10.1186/s13045-019-0746-1

Verify or expand the search:

Other trials of Avelumab

Trials testing the same drug.

NCT06939036 — Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) · Phase 1, PHASE2 · terminated
NCT05687721 — Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer · Phase 1, PHASE2 · withdrawn
NCT06518564 — Avelumab and M1774 in ARID1A-mutated Endometrial Cancer · Phase 2 · recruiting
NCT06424717 — Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L · Phase 2 · withdrawn
NCT06302426 — Trial of INI-4001 in Patients With Advanced Solid Tumours · Phase 1 · recruiting

Other recruiting trials for Diffuse Large B-Cell Lymphoma

Currently open trials in the same condition.

NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07200375 — An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma · recruiting
NCT07070648 — Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ct · recruiting
NCT07001540 — Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola · Phase 2 · recruiting
NCT06803693 — Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL · Phase 2 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02951156 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 17 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02951156.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing